Alpha 2.0
Login Register
» Articles » PMID: 37356031

Addendum. 3. Prevention or Delay of Type 2 Diabetes and Associated Comorbidities: Standards of Care in Diabetes-2023. Diabetes Care 2023;46(Suppl. 1):S41-S48

Overview
Journal Diabetes Care
Specialty Endocrinology
Date 2023 Jun 25
PMID 37356031
Authors
Nuha A ElSayed
Grazia Aleppo
Vanita R Aroda
Raveendhara R Bannuru
Florence M Brown
Dennis Bruemmer
Billy S Collins
Marisa E Hilliard
Diana Isaacs
Eric L Johnson
Scott Kahan
Kamlesh Khunti
Jose Leon
Sarah K Lyons
Mary Lou Perry
Priya Prahalad
Richard E Pratley
Jane Jeffrie Seley
Robert C Stanton
Robert A Gabbay
Affiliations
Soon will be listed here.
Citing Articles

The role of glucagon-like peptide-1 receptor agonists (GLP1-RAs) in the management of the hypertensive patient with metabolic syndrome: a position paper from the Korean society of hypertension.

Lee H, Ko S, Park S, Kim K, Kim S, Cho I Clin Hypertens. 2024; 30(1):24.

PMID: 39217384 PMC: 11366170. DOI: 10.1186/s40885-024-00279-4.

Vitamin D Status and Cardiovascular Risk Factors in Patients with Type 2 Diabetes Mellitus: A Cross-Sectional Study in a Tertiary-Level Hospital in Antananarivo, Madagascar.

Raharinavalona S, Raherison R, Miandrisoa R, Andrianasolo R, Rakotomalala A Diabetes Metab Syndr Obes. 2024; 17:2191-2198.

PMID: 38835729 PMC: 11149705. DOI: 10.2147/DMSO.S467316.

Gout risk in adults with pre-diabetes initiating metformin.

Marrugo J, Santacroce L, Paudel M, Fukui S, Turchin A, Tedeschi S Ann Rheum Dis. 2024; 83(10):1368-1374.

PMID: 38749572 PMC: 11442121. DOI: 10.1136/ard-2024-225652.

The Impact of a Nutritional Intervention on Glycemic Control and Cardiovascular Risk Markers in Type 2 Diabetes.

Minari T, Manzano C, Tacito L, Yugar L, Sedenho-Prado L, de Azevedo Rubio T Nutrients. 2024; 16(9).

PMID: 38732624 PMC: 11085322. DOI: 10.3390/nu16091378.

American College of Lifestyle Medicine Expert Consensus Statement: Lifestyle Medicine for Optimal Outcomes in Primary Care.

Grega M, Shalz J, Rosenfeld R, Bidwell J, Bonnet J, Bowman D Am J Lifestyle Med. 2024; 18(2):269-293.

PMID: 38559790 PMC: 10979727. DOI: 10.1177/15598276231202970.

References
1.
Herold K, Bundy B, Long S, Bluestone J, DiMeglio L, Dufort M . An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. N Engl J Med. 2019; 381(7):603-613. PMC: 6776880. DOI: 10.1056/NEJMoa1902226. View